The role of endoscopy in dyspepsia

Prepared by: ASGE STANDARDS OF PRACTICE COMMITTEE
Aasma Shaukat, MD, MPH, FASGE, Amy Wang, MD, Ruben D. Acosta, MD, David H. Bruining, MD, Vinay Chandrasekhar, MD, Krishnavel V. Chatthadi, MD, Mohamad A. Eloubeidi, MD, MHS, FASGE, Robert D. Fanelli, MD, FACS, FASGE, SAGES Representative, Ashley L. Faulx, MD, FASGE, Lisa Fonkalsrud, BSN, RN, CGRN, Suryakanth R. Gurudu, MD, FASGE, Loralee R. Kelsey, BSN, RN, CGRN, SGNA Representative, Mouen A. Khashab, MD, Shivangi Kothari, MD, Jennifer R. Lightdale, MD, MPH, FASGE, NASPghan Representative, V. Raman Muthusamy, MD, FASGE, Shabana F. Pasha, MD, John R. Saltzman, MD, Julie Yang, MD, Brooks D. Cash, MD, Previous Committee Chair, John M. DeWitt, MD, FASGE, Chair

This document was reviewed and approved by the governing board of the American Society for Gastrointestinal Endoscopy.

Dyspepsia encompasses a constellation of upper abdominal symptoms affecting 20% to 40% of the population in Western countries. Many patients with dyspepsia are referred to gastroenterologists for consultation and endoscopy. Given this large burden of referral patients, the appropriate role of endoscopy in the evaluation of dyspepsia is both a pragmatic concern for the gastroenterologist and an important determinant of health care costs.

DEFINITION

Dyspepsia is a poorly characterized syndrome thought to originate from anatomic or functional disorders of the upper GI tract. Dyspepsia encompasses a variety of symptoms including epigastric discomfort, bloating, anorexia, early satiety, belching or regurgitation, nausea, and heartburn. Rome III criteria define dyspepsia as 1 or more of the following 3 symptoms for 3 months within the initial 6 months of symptom onset: (1) postprandial fullness, (2) early satiety, and (3) epigastric pain or burning.

The symptoms of dyspepsia overlap significantly with those associated with peptic ulcer disease (PUD), GERD, other functional disorders such as epigastric pain syndrome and irritable bowel syndrome, malignancy, adverse effects of medications, pancreatitis, biliary tract disease, vascular disease, and motility disorders. The prevalence of GERD and irritable bowel syndrome is higher in patients with dyspepsia compared with patients without dyspepsia. Despite the nonspecific nature of symptoms, dyspepsia is associated with poor health-related quality of life and greater psychological distress.

For the purposes of this guideline, the ROME III criteria are used, recognizing that practitioners may refer patients with a diagnosis of dyspepsia who experience less-clearly defined symptoms. Patients with GERD are excluded from this guideline. Additional information regarding the
PATIENTS WITHOUT ALARM FEATURES

Dyspeptic patients younger than 50 years of age and without alarm features are commonly evaluated by 1 of 3 methods: (1) noninvasive testing for *Helicobacter pylori*, with subsequent treatment if positive (the “test and treat” approach), (2) an empiric trial of acid suppression, or (3) initial endoscopy.

**Test and treat**

The rationale for testing and treating *H pylori* in patients with dyspepsia is that *H pylori* may be associated with true pathologic disorders of the upper GI tract, such as PUD or gastritis, and that eradication may result in reversal or stabilization of the abnormal pathology and improvement in symptoms. Nevertheless, there is no known mechanism to explain a reduction in symptoms by treating *H pylori* in patients with dyspepsia and no pathologic disorders. Several large randomized, controlled trials have evaluated the benefit of empiric *H pylori* treatment in dyspeptic patients. Systematic reviews show that, compared with initial endoscopy, a “test and treat” approach may provide modest improvement in symptoms 

The role of endoscopy in dyspepsia

### TABLE 1. GRADE system for rating the quality of evidence for guidelines

<table>
<thead>
<tr>
<th>Quality of evidence</th>
<th>Definition</th>
<th>Symbol</th>
</tr>
</thead>
<tbody>
<tr>
<td>High quality</td>
<td>Further research is very unlikely to change our confidence in the estimate of effect.</td>
<td>⭐⭐⭐⭐</td>
</tr>
<tr>
<td>Moderate quality</td>
<td>Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.</td>
<td>⭐⭐⭐</td>
</tr>
<tr>
<td>Low quality</td>
<td>Further research is likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.</td>
<td>⭐⭐</td>
</tr>
<tr>
<td>Very low quality</td>
<td>Any estimate of effect is very uncertain.</td>
<td>⭐</td>
</tr>
</tbody>
</table>

Adapted from Guyatt et al.53

### TABLE 2. Alarm features for dyspeptic patients

<table>
<thead>
<tr>
<th>Alarm feature</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age ≥50 years</td>
</tr>
<tr>
<td>Family history of upper GI malignancy in a first-degree relative</td>
</tr>
<tr>
<td>Unintended weight loss</td>
</tr>
<tr>
<td>GI bleeding or iron deficiency anemia</td>
</tr>
<tr>
<td>Dysphagia</td>
</tr>
<tr>
<td>Odynophagia</td>
</tr>
<tr>
<td>Persistent vomiting</td>
</tr>
<tr>
<td>Abnormal imaging suggesting organic disease</td>
</tr>
</tbody>
</table>

management of GERD can be found in a previously published document.17
difficile–associated colitis and induction of antibiotic resistance.27,28 It is important to note that the prevalence rates of *H pylori* in the United States are lower than in developing countries and may vary by region and target population. Hence, testing and treating for *H pylori* may be relevant and cost-effective in regions with prevalence rates of *H pylori* of 20% or higher.28–30 Noninvasive testing options for *H pylori* include serology, urea breath testing, and stool antigen testing. Serologic testing has a sensitivity and specificity ranging from 85% to 100% and 76% to 96%, respectively.30,31 The specificity of urea breath testing and stool antigen is higher than that of serologic testing.32 In summary, an initial “test and treat” strategy may be a reasonable and possibly cost-effective approach for the management of younger patients with dyspepsia and no alarm features in regions with a higher prevalence of *H pylori* infection.

**Empiric acid suppression therapy**

Many authors and societies advocate acid suppressive therapy as the initial strategy for dyspeptic patients.18,19,33 These benefits are seen primarily in patients with dyspepsia who have reflux-type symptoms, rather than dysmotility- or nausea-type symptoms. For the treatment of dyspepsia symptoms, empiric proton pump inhibitors (PPIs) are more effective than antacids and histamine receptor antagonists.34,35 Several randomized, controlled clinical trials have demonstrated the benefit of PPIs compared with placebo in treating symptoms of dyspepsia with absolute risk reductions of 10%36 to 17%.37 A meta-analysis of 7 studies showed that PPIs were superior to placebo for reducing dyspeptic symptoms (relative risk reduction, 10%; 95% confidence interval [CI], 2.7%–17.3%)38 with a significant benefit in treatment efficacy evident only in the reflux-type symptom group and not in those with dysmotility-like symptoms. Initiation of empiric acid suppression will not address underlying *H pylori* infection in patients with *H pylori*–associated PUD, a strategy that may risk recurrence of symptoms when acid suppression is withdrawn. This approach may also lead to long-term acid suppression if no further investigation is performed.39 In 1 study comparing PPI therapy with the “test and treat” approach in patients younger than 45 years of age, endoscopy was used more frequently in the PPI treatment group (88% vs 55%; *P* < .001).40 A decision analysis showed that cost-effectiveness of the “test and treat” approach versus empiric acid suppression depends on the prevalence of *H pylori*. In these patients, the prevalence rates of dyspepsia symptoms or quality of life, but the endoscopic arm was more costly.46 Other studies show mixed results with respect to cost-effectiveness.47,48 It is unclear whether patients with dyspepsia whose symptoms are controlled with prolonged PPI use should undergo endoscopy. Endoscopy may still be considered in the group of nonresponders to exclude structural disease.43 A potential advantage of a negative endoscopy in the evaluation of dyspeptic patients is a reduction in anxiety and an increase in patient satisfaction,49,50 yet there is little evidence to suggest significant improvement in outcomes by this approach.

**Endoscopy-negative, persistent dyspepsia**

Many patients with dyspepsia and negative findings on endoscopy continue to experience symptoms despite acid suppression and/or *H pylori* eradication. These patients can be difficult to manage. The majority have functional dyspepsia, for which treatment options include stopping nonsteroidal anti-inflammatory drugs, a trial of antispasmodics, dietary and lifestyle changes, prokinetic agents, sucralfate, simethicone, tricyclic antidepressants, selective serotonin reuptake inhibitors, and cognitive behavior therapy.51,52 More research is required to understand the pathophysiology of symptoms in these patients and the role of medications and other therapies. Other conditions that may cause upper abdominal pain or discomfort (which may be confused with dyspepsia) should be considered, including irritable bowel syndrome, GERD, gastroparesis, pancreatic or biliary disorders, celiac
disease, and other functional disorders. Further testing is warranted in patients with pain that is worsening or atypical for dyspepsia or that is accompanied by other worrisome symptoms or signs but should be avoided in young patients with presumed functional disease.

A suggested algorithmic approach to dyspepsia is shown in Figure 1.

**RECOMMENDATIONS**

1. We recommend initial endoscopy for new-onset dyspepsia in patients 50 years of age or older or those with alarm features.
2. We recommend that dyspeptic patients younger than 50 years of age and without alarm features undergo either an initial “test and treat” approach for *Helicobacter pylori* or empiric therapy with a PPI, depending on the prevalence of *H pylori* infection in their population. For *H pylori* prevalence greater than 20%, “test and treat” is recommended.
3. We suggest that dyspeptic patients who are younger than 50 years of age, lack alarm features, and are *H pylori* negative may be offered a trial of PPI acid suppression.
4. We suggest that endoscopy be performed in dyspeptic patients who are *H pylori* negative and do not respond to empiric PPI therapy.

**DISCLOSURES**

Dr Fanelli is the owner and director of New Wave Surgical Inc, is an advisor for and receives royalties from Cook Medical, is a consultant for Endogastric Solutions, and is an owner of Allurion Technologies Inc and Mozatic Medical Inc. Dr Khashab is a consultant for and on the advisory board of Boston Scientific, a consultant for Olympus, and has received research support from Cook Medical. Dr Muthusamy is a consultant for Boston Scientific and Capividen GI Solutions and a stockholder in Capsovision Inc. Dr Chandrasekhar is a consultant for Boston Scientific. Dr Chathadi is a consultant for Boston Scientific. All other authors disclosed no financial relationships relevant to this article.

**REFERENCES**


The role of endoscopy in dyspepsia


GIE on Twitter

GIE now has a Twitter account. Followers will learn when the new issues are posted and will receive up-to-the-minute news as well as links to author interviews, podcasts, and articles. Search on Twitter for @GIE_Journal and follow all of GIE’s tweets.